Vaccine delivery method
Inventors
Harn, Donald A. • QUEIROZ, RAFAELLA • Shollenberger, Lisa • Samli, Emily-Joy Farrah
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12186390-B2
Publication Date
2025-01-07
Expiration Date
Abstract
A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.
Core Innovation
The invention provides a vaccine composition comprising a peptide hydrogel of the peptide scaffold RADARADARADARADA (SEQ ID NO:2). The composition includes an antigen selected from a hepatitis antigen, a human immunodeficiency virus (HIV) antigen, a tuberculosis antigen, or an influenza antigen, and a TLR9 agonist or a Toll-Like Receptor (TLR) agonist.
The vaccine composition is liquid at room temperature in a non-physiological pH and/or non-physiological salt concentrations, and gels at physiological pH, physiological salt concentrations and/or physiological temperatures. In related embodiments, it gels after administration to a subject.
Claims Coverage
The independent claims are clm-00001, clm-00010, and clm-00015. Across these claims, there are 4 main inventive features covering the RADARADARADARADA peptide hydrogel vaccine composition, antigen selection, a TLR agonist component, and the liquid-to-gel formulation behavior under non-physiological and physiological conditions.
RADARADARADARADA peptide hydrogel-based vaccine composition
A vaccine composition comprising a peptide hydrogel of the peptide scaffold RADARADARADARADA (SEQ ID NO:2).
Antigen selection for hepatitis, HIV, tuberculosis, and influenza
The antigen is selected from a hepatitis antigen, a human immunodeficiency virus (HIV) antigen, a tuberculosis antigen, or an influenza antigen.
TLR9 agonist or Toll-Like Receptor agonist in the vaccine composition
The vaccine composition includes a TLR9 agonist or a Toll-Like Receptor (TLR) agonist.
Non-physiological liquid at room temperature and physiological gelling
The vaccine composition is liquid at room temperature in non-physiological pH and/or non-physiological salt concentrations and gels at physiological pH, physiological salt concentrations and/or physiological temperatures, including gelling after administration to a subject.
The claimed vaccine compositions center on a RADARADARADARADA (SEQ ID NO:2) peptide hydrogel that remains liquid under non-physiological conditions and gels under physiological conditions and after administration, with antigens selected from hepatitis, HIV, tuberculosis, and influenza, together with a TLR9 agonist or a Toll-Like Receptor (TLR) agonist.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?